Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes

Neuropsychopharmacology

Volumn 20, Issue 6, 1999, Pages 612-627

  Lawler, Cindy P ^a,b   Prioleau, Cassandra ^a,b   Lewis, Mechelle M ^a,b   Mak, Chun ^c   Jiang, Dong ^c   Schetz, John A ^c   Gonzalez, Antonio M ^c   Sibley, David R ^c   Mailman, Richard B ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c National Institute of Neurological Disorders   (United States)

Author keywords

Adenylyl cyclase; Antipsychotic; Aripiprazole; C 6 cells; CHO cells; Dopamine receptors; Functional selectivity; Schizophrenia

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 7 [3 [4 (2,3 DIMETHYLPHENYL) 1 PIPERAZINYL]PROPOXY] 2(1H) QUINOLINONE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ARIPIPRAZOLE; CHLORPROMAZINE; CYCLIC AMP; DM 1451; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; DRUG METABOLITE; ETICLOPRIDE; HALOPERIDOL; NEUROLEPTIC AGENT; QUINPIROLE; RECEPTOR SUBTYPE; SEROTONIN RECEPTOR; SPIPERONE; SULPIRIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL LINE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG RECEPTOR BINDING; GLIOMA CELL; IN VITRO STUDY; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; CHO CELLS; CORPUS STRIATUM; CRICETINAE; GLIOMA; PIPERAZINES; QUINOLONES; RATS; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; TUMOR CELLS, CULTURED;

EID: 0033151286     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00099-2     Document Type: Article

References (79)

1. Amano T., Matsubayashi H., Momiyama T., Ishihara K., Todo N., Sasa M. Antagonizing effects of a novel antipsychotic quinolinone derivative (OPC-14597) on dopaminergic inhibition of neuronal activities in the nucleus accumbens. Prog Neuropsychopharmacol Biol Psych. 19:1995;105-116.
2. Arana G.W., Hyman S.E. Handbook of Psychiatric Drug Therapy. 2nd ed:1991;Little, Boston. Brown, and Company, pp 27-34.
3. 4 dopamine receptor protein in the CNS using antireceptor antisera. Brain Res. 752:1997;26-34.
4. Arnt J., Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology. 18:1998;63-101.
5. Boess F.G., Martin I.L. Molecular biology of 5-HT receptors. Neuropharmacology. 33:1994;275-317.
6. 1 full agonist J Med Chem. 33:1990;1756-1764.
7. 2 dopamine receptor cDNA. Nature. 336:1988;783-787.
8. Clark D., Hjorth S., Carlsson A. Dopamine receptor agonists. Mechanisms underlying autoreceptor selectivity. I. Review of the evidence J Neural Transm. 62:1985;1-52. a.
9. Clark D., Hjorth S., Carlsson A. Dopamine receptor agonists. Mechanisms underlying autoreceptor selectivity II. Theoretical considerations J Neural Trans. 62:1985;171-207. b.
10. 2 receptors. Implications for drug mechanisms of action Life Sci. 39:1986;2571-2580.
11. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 192:1976;481-483.
12. 1 dopamine receptor. Nature. 347:1990;72-76.
13. Deutsch S.I., Mastropaolo J., Schwartz B.L., Rosse R.B., Morisha J.M. A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine. Clin Neuropharmacol. 12:1989;1-13.
14. 3 receptor in the rat brain. Neuroscience. 65:1995;731-745.
15. s. Mol Pharmacol. 45:1994;696-702.
16. Fatemi H.S., Meltzer H.Y., Roth B.L. Atypical antipsychotic drugs. Clinical and preclinical studies Csernansky J.G. Handbook of Experimental Pharmacology. Antipsychotics, vol. 120:1996;77-115 Springer-Verlag, New Jersey.
17. Garau L., Govoni S., Stefanini E., Trabucchi M., Spano P.F. Dopamine receptors. Pharmacological and anatomical evidences indicate that two distinct dopamine receptor populations are present in rat striatum Life Sci. 23:1978;1745-1750.
18. Gerlach J. New Antipsychotics. classification, efficacy, and adverse effects Schizophr Bull. 17:1991;97-117.
19. 1A receptor. Biochem. 33:1994;4283-4290.
20. 2 dopamine receptor isoforms. Nature. 342:1989;923-926.
21. Gurwitz D., Haring R., Heldman E., Fraser C.M., Manor D., Fisher A. Discrete activation of transduction pathways associated with acetylcholine m1 receptors by several muscarinic ligands. Eur J Pharmacol. 267:1994;21-31.
22. Harper J.F., Brooker G. Femtomole sensitive radioimmunoassay for cyclic AMP and cyclic GMP after 2′O-acetylation by acetic anhydride in aqueous solution. J Cyclic Nucleotide Res. 1:1975;207-218.
23. Hartman D.S., Civelli O. Molecular attributes of dopamine receptors. New potential for antipsychotic drug development Ann Med. 28:1996;211-219.
24. Inoue K., Koizumi S., Ueno S. Implication of ATP receptors in brain functions. Prog Neurobiol. 50:1996;483-492.
25. 2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol. 321:1997;105-111.
26. Jeste D.V., Caligiuri M.P. Tardive dyskinesia. Schizophr Bull. 19:1993;303-315.
27. 2 receptors to neuronal circuits in human brain. Insights into schizophrenia Neuropsychopharmacology. 16:1997;375-384.
28. 2 receptor interactions in animal models of schizophrenia. Eur J Pharmacol. 295:1996;147-154.
29. Kane J., Hoingfeld G., Singer J., Meltzer H., Cozaril Collaborative Study Group Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiat. 45:1988;789-796.
30. Kaplan H.I., Sadock B.J. Synopsis of Psychiatry. 5th ed:1988;Williams & Wilkins, Baltimore. 254 pp.
31. Kebabian J., Calne D.B. Multiple receptors for dopamine. Nature. 277:1979;93-96.
32. Kenakin T. Pharmacological Analysis of Drug-Receptor Interactions. 1993;New York, Raven Press. pp 249-277.
33. Kenakin T. Agonist-receptor efficacy II. Agonist trafficking of receptor signals Trends Pharmacol Sci. 16:1995;232-238.
34. 2 receptor antagonistic activity. J Pharmacol Exp Ther. 274:1995;329-336.
35. 2 dopamine receptor. Soc Neurosci Abstr. 23:1997;1777.
36. 2 receptors Soc Neurosci Abstr. 22:1996;1769.
37. 4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. Arch Gen Psychiat. 4:1997;567-572.
38. Lader M.H. Neuroleptic-induced deficit syndrome (NIDS). J Clin Psychiat. 54:1993;493-500.
39. Lahti A.C., Wiler M.A., Corey P.K., Lahti R.A., Carlsson A., Tamminga C.A. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpeperidine (preclamol) in schizophrenia. Biol Psychiat. 43:1998;2-11.
40. 2 receptor selectivity of dopamine receptor antagonists. Possible therapeutic implications Eur J Pharmacol. 236:1993;483-486.
41. Leff P., Scaramellini C., Law C., McKechnie K. A three-state model of agonist action. Trends Pharmacol Sci. 18:1997;355-362.
42. Mailman R.B., Nichols D.E., Lewis M.M., Blake B., Lawler C.P. Functional effects of novel dopamine ligands. Dihydrexidine and Parkinson's disease as a first step Jenner P., Demirdemar R. Dopamine Receptor Subtypes. From Basic Science to Clinic:1997;Amsterdam, IOS Stockton Press.
43. Meltzer H.Y. The mechanism of action of novel antipsychotic drugs. Schizophr Bull. 17:1991;263-287.
44. 1 dopamine receptor linked to adenylyl cyclase activation. Proc Natl Acad Sci. 87:1990;6723-6727.
45. 2 dopamine receptors produced by alternative RNA splicing. Nature. 342:1989;926-929.
46. Monsma F.J., Shen Y., Ward R.P., Hamblin M.W., Sibley D.R. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Molec Pharmacol. 43:1993;320-327.
47. Momiyama T., Sasa M., Takaori S. D-2 receptor-mediated inhibition by a substituted quinolinone derivative, 7-[3-(4-(2,3-dimethylphenyl)piperazinyl)propoxy]-2(1H)-quinolinone (OPC-4392), of dopaminergic neurons in the ventral tegmental area. Life Sci. 47:1990;761-769.
48. Momiyama T., Amano T., Todo N., Sasa M. Inhibition by a putative antipsychotic quinolinone derivative (OPC-14597) of dopaminergic neurons in the ventral tegmental area. Eur J Pharmacol. 310:1996;1-8.
49. 1 dopamine receptor agonist. J Pharmacol Exp Ther. 262:1992;383-393.
50. Motulsky H.J., Ransnas L.A. Fitting curves to data using nonlinear regression. a practical and nonmathematical review FASEB J. 1:1987;365-374.
51. 2 receptors by sodium and pH. Mol Pharmacol. 39:1991;570-578.
52. 125I]epidepride, a high-affinity substituted benzamide ligand. J Pharmacol Exp Ther. 252:1990;1108-1116.
53. 2 receptor dimers and receptor-blocking peptides. Biochem Biophys Res Commun. 227:1996;200-204.
54. 125I-labeled succinyl cyclic nucleotide tyrosine methyl esters by high-performance liquid chromatography. Analyt Biochem. 168:1988;417-420.
55. Peacock L., Gerlach J. Antipsychotic-induced side effects related to receptor affinity. Csernansky J.G. Handbook of Experimental Pharmacology. Antipsychotics, vol. 120:1996;359-388 Springer-Verlag, New York.
56. 2 receptor as revealed by polymerase chain reaction. FEBS. 263:1990;18-22.
57. Raymond J.R. Multiple mechanisms of receptor-G protein signaling specificity. Am J Physiol. 269:1995;F141-F158.
58. 7 serotonin receptors. J Pharm Exp Therap. 268:1994;1403-1410.
59. Seeman P., Lee T., Chan-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 261:1976;717-719.
60. 4 receptors. Neuropsychopharmacology. 16:1997;93-110.
61. Semba J., Sakai M., Miyoshi R., Mataga N., Fukamauchi F., Kito S. Differential expression of c-fos mRNA in rat prefrontal cortex, sriatum, nucleus accumbens, and lateral septum after typical and atypical antipsychotics. An in situ hybridization study Neurochem Int. 29:1996;435-442.
62. 7 serotonin receptor subtype. J Biol Chem. 268:1993;18200-18204.
63. 2 dopamine receptors coupled to adenylyl cyclase, but not to potassium ion channels. Soc Abstr Neurosci. 22:1996;1316.
64. 2 receptor splice variants by solution hybridization/protection assay. Neurosci Lett. 122:1991;37-40.
65. 3) as a target for neuroleptics. Nature. 347:1990;146-151.
66. Spengler D., Waeber C., Pantaloni C., Holsboer F., Bockaert J., Seeburg P.H., Journot L. Differential signal transduction by five splice variants of the PACAP receptor. Nature. 365:1993;170-175.
67. 1 receptor encoded by an intronless gene on chromosome 5. Nature. 347:1990;80-83.
68. 1. Nature. 250:1991;614-619.
69. 4 dopamine receptors in fibroblast and dopaminergic cell lines. J Pharmacol Exp Ther. 268:1994;495-502.
70. 1A receptor Proc Natl Acad Sci. 88:1991;7491-7495.
71. Toru M., Miura S., Kudo Y. Clinical experiences of OPC-14597, a dopamine autoreceptor agonist in schizophrenic patients. Neuropsychopharmacology. 10:1994;122S.
72. 2 receptors expressed in different cell types. J Biol Chem. 265:1990;10320-10326.
73. Van Kammen D.P., Peters J., Yao J., Van Kammen W.B., Neylan T., Shaw D., Linnoila M. Norepinephrine in acute exacerbations of chronic schizophrenia. Negative symptoms revisited. Arch General Psychiat. 47:1990;161-168.
74. 4 receptor with high affinity for the antipsychotic clozapine. Nature. 350:1991;610-614.
75. 1 dopamine receptor agonists Synapse. 21:1995;177-187.
76. Wyrick S., Mailman R.B. Tritium labeled (±)-7-chloro-8-hydroxy-3-methyl-l-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SCH23390). J Labeled Compd Radiopharmac. 22:1985;189-195.
77. 2 receptor antagonist. Life Sci. 42:1988;1941-1954.
78. 21 dopamine receptor isoforms are differentially regulated in Chinese hamster ovary cells. Molec Pharmacol. 45:1994;878-889.
79. 1 dopamine receptors. Nature. 247:1990;76-80.